{{Rsnum
|rsid=2020927
|Gene=ABCA1
|Chromosome=9
|position=104790904
|Orientation=minus
|GMAF=0.3118
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ABCA1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.9 | 20.4 | 78.8
| HCB | 17.5 | 48.9 | 33.6
| JPT | 11.5 | 48.7 | 39.8
| YRI | 36.1 | 48.3 | 15.6
| ASW | 26.3 | 40.4 | 33.3
| CHB | 17.5 | 48.9 | 33.6
| CHD | 13.8 | 52.3 | 33.9
| GIH | 6.9 | 35.6 | 57.4
| LWK | 34.5 | 56.4 | 9.1
| MEX | 3.4 | 29.3 | 67.2
| MKK | 33.5 | 52.3 | 14.2
| TSI | 2.0 | 21.6 | 76.5
| HapMapRevision=28
}}{{PMID|17510949}}  [[rs2297404]], [[rs2230808]], and [[rs2020927]] haplotype (CAC) was more prevalent in the [[Alzheimer's disease]] group (0.323 in AD vs. 0.202 in control); while haplotype1 (TGG) was over-represented in the healthy controls (0.595 in control vs. 0.493 in AD)

{{PMID|19538231}} Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone.

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}